anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
AIMS: The optimal revascularization strategy for patients with acute myocardial infarction (AMI), cardiogenic shock (CS), and multivessel disease remains controversial. The CULPRIT-SHOCK trial compared culprit lesion-only vs. immediate multivessel percutaneous coronary intervention (PCI), providing important data but leaving efficacy questions unresolved. To address lingering uncertainties and gain deeper insights, we performed a Bayesian reanalysis of the CULPRIT-SHOCK trial data.
METHODS AND RESULTS: We conducted a Bayesian re-analysis of the CULPRIT-SHOCK trial data using non-informative, sceptical, and enthusiastic priors. Relative risks (RRs) with 95% highest posterior density (HPD) intervals were calculated. We defined the minimal clinically important difference (MCID) as RR < 0.84. We performed subgroup analyses for key patient characteristics and assessed secondary outcomes and safety endpoints. Probabilities of benefit, achieving MCID, and harm were computed. Results are presented as median RR with probabilities of effect sizes. Bayesian reanalysis showed a median RR of 0.82 (95% HPD 0.66-1.04) with a non-informative prior, indicating a 95% probability of benefit and 59% probability of achieving MCID. Subgroup analyses revealed potentially stronger effects in males (RR 0.78, 73% probability of MCID), patients without diabetes (RR 0.76, 79% probability of MCID), and those with non-anterior ST-segment elevation MI (STEMI; RR 0.74, 76% probability of MCID). Secondary outcomes suggested potential benefits in mortality (RR 0.85) and need for renal replacement therapy (RR 0.72) but increased risks of recurrent MI (RR 2.84) and urgent revascularization (RR 2.88).
CONCLUSION: Our Bayesian reanalysis provides intuitive insights by quantifying probabilities of treatment effect sizes, offering further evidence favouring the culprit lesion-only PCI strategy in AMI patients with CS and multivessel disease. The analysis demonstrates a high probability of overall benefit, with a notable chance of achieving a minimally clinically important difference, particularly in specific subgroups. These findings not only support the consideration of culprit lesion-only PCI in certain patient populations but also underscore the need for careful risk-benefit assessment. Furthermore, our hypothesis-generating subgroup analyses, which show varying probabilities of achieving MCID, illuminate promising avenues for future targeted investigations in this critical patient population.
This is a randomized, double-blind, placebo-controlled, inpatient/outpatient study to assess the safety, pharmacokinetics, and pharmacodynamics of SRT501 in subjects diagnosed with colorectal cancer and hepatic metastases. Fifteen subjects aged 18 years of age and older who fulfill the inclusion/exclusion criteria, will be enrolled in this study. Ten subjects, if eligible, will be randomized to receive SRT501 and 5 subjects, if eligible, will be randomized to receive placebo. Subjects will sign the informed consent form prior to any study-related procedures. If eligible, subjects will consent to receive 5.0 g of SRT501 or placebo, to be administered once daily as an oral reconstituted powder, for 14 days at the same time each day. On Days 1 and 2, SRT501 or placebo will be administered approximately 15-30 minutes following the consumption of a standardized breakfast to allow for PK sample collection. On all other days, SRT501 or placebo will be administered approximately 15-30 minutes following the consumption of the evening meal. Following the course of SRT501 or placebo administration, subjects will undergo scheduled surgical removal of their metastatic liver disease as well as non-diseased tissue and these samples will be evaluated for SRT501 concentrations and pharmacodynamic markers of neoplastic activity (such as cell differentiation, apoptosis, proliferation, etc.). Due to scheduling and surgical availability, subjects can receive SRT501 or placebo for a minimum of 10 days and a maximum of 21 days. If diseased colon tissue is also scheduled to be removed during resection, both diseased and normal colon tissue will also be collected for analysis. Participants will be required to return to the study center on Day 2 for a 24-hour PK sample and the evening prior to their scheduled surgical resection as well as per the Institution's standards of care for recovery following the surgical procedure.
Recently, inertial measurement units have been gaining popularity as a potential alternative to optical motion capture systems in the analysis of joint kinematics. In a previous study, the accuracy of knee joint angles calculated from inertial data and an extended Kalman filter and smoother algorithm was tested using ground truth data originating from a joint simulator guided by fluoroscopy-based signals. Although high levels of accuracy were achieved, the experimental setup leveraged multiple iterations of the same movement pattern and an absence of soft tissue artefacts. Here, the algorithm is tested against an optical marker-based system in a more challenging setting, with single iterations of a loaded squat cycle simulated on seven cadaveric specimens on a force-controlled knee rig. Prior to the optimisation of local coordinate systems using the REference FRame Alignment MEthod (REFRAME) to account for the effect of differences in local reference frame orientation, root-mean-square errors between the kinematic signals of the inertial and optical systems were as high as 3.8° ± 3.5° for flexion/extension, 20.4° ± 10.0° for abduction/adduction and 8.6° ± 5.7° for external/internal rotation. After REFRAME implementation, however, average root-mean-square errors decreased to 0.9° ± 0.4° and to 1.5° ± 0.7° for abduction/adduction and for external/internal rotation, respectively, with a slight increase to 4.2° ± 3.6° for flexion/extension. While these results demonstrate promising potential in the approach's ability to estimate knee joint angles during a single loaded squat cycle, they highlight the limiting effects that a reduced number of iterations and the lack of a reliable consistent reference pose inflicts on the sensor fusion algorithm's performance. They similarly stress the importance of adapting underlying assumptions and correctly tuning filter parameters to ensure satisfactory performance. More importantly, our findings emphasise the notable impact that properly aligning reference-frame orientations before comparing joint kinematics can have on results and the conclusions derived from them.
The present invention relates to genes and protein encoded thereby that regulate the secretory pathway and/or the neuroendocrine phenotype (NEP) in cells and method of isolating same. More particularly, the present invention relates to long-term therapies for diseases or conditions associated with a loss function. More particularly, the present invention relates to the treatment of such diseases using a cell replacement therapy. In particular, the invention relates to genes involved in cellular differentiation and genes that modulate the formation of the regulated secretory pathway. The invention thus also concerns a method to identify such genes, the genes, variants or fragments thereof, vectors comprising same, the products of these genes, variants or fragments thereof and to cells expressing same. In a particular embodiment, the invention relates to the characterization of Zis-SR a novel sequence involved in the secretory pathway in cells.
Type 2 diabetes (T2D) is a common noncommunicable disease. In the United States alone, 37 million Americans had diabetes in 2017. The adzuki bean (Vigna angularis), a legume, has been reported to possess antidiabetic benefits. However, the extent and specific mechanisms through which adzuki bean consumption may contribute to T2D prevention and management remain unclear. Therefore, the aim of this narrative review is to analyze current evidence supporting the utilization of adzuki beans in the diet as a strategy for preventing and managing T2D. Animal studies have demonstrated a positive impact of adzuki beans on managing T2D. However, supporting data from humans are limited. Conversely, the potential of adzuki bean consumption in preventing T2D via modulating two T2D risk factors (obesity and dyslipidemia) also lacks conclusive evidence. Animal studies have suggested an inconsistent and even contradictory relationship between adzuki bean consumption and the management of obesity and dyslipidemia, in which both positive and negative relationships are reported. In sum, based on the existing scientific literature, this review found that the effects of adzuki bean consumption on preventing and managing T2D in humans remain undetermined. Consequently, human randomized controlled trials are needed to elucidate the potential benefits of the adzuki bean and its bioactive components in the prevention and management of T2D.
PURPOSE:To provide an antineoplastic agent having a combination of macrobiotic activity and tumor-reducing activity, promising usefulness even in patients with terminal cancer or cachexia. CONSTITUTION:The antineoplastic agent consisting of a combination of (A) a biophylaxis activator, e.g. lenthinan, sonifilan, krestin, (B) human interleukin 2 or human interleukin 2-productive derivative, e.g. a plasmid built up in such a form as to be capable of manifesting in mammalian cells hormones, nucleic acid derivatives, amino acid derivatives or human interleukin 2 gene, and (C) a cancer cachexia inhibitor, e.g. arachidonic acid metabolite production inhibitor, inflammatory cytokinin (TGF-beta, TNF, IL-6, etc.) production or activity inhibitor, neoplastic blood vessel proliferation inhibitor. The component C further includes an agent to selectively deplete anti-inflammatory macrophages or to inhibit derivation of said cells, active oxygen scavenger or a derivative therefrom, and prodrug of cancer chemical therapeutic agent which is converted to an active modification by an enzyme potentiated at cancer loci with the advance of cancer cachexia.
The invention discloses a high-flux preparation method of therapeutic protein nanoparticles. The method comprises the following steps: firstly, converting hydrophilic protein drugs into protein-lipid complexes by using a hydrophobic ion pair method, then diluting the protein-lipid complexes by using an organic solvent which is mutually soluble with water, and then preparing the protein nanoparticles by using a rapid nano-precipitation method. Compared with the traditional preparation method of the protein nanoparticles, the method has the greatest advantages that the method can be used for continuous large-scale production, the productivity can reach 1.2 g/h, and the production capacity is far higher than that of the traditional preparation method of the protein nanoparticles. In addition, the rapid nano-precipitation method can be used for continuous production, has small difference among batches, and is suitable for industrial production. Further, the hyaluronic acid coated on the surface of the protein particles prepared by the present invention can impart stability for long-term storage and mucus penetration to the protein drug nanoparticles. The protein nano-particles prepared by the method have a wide application prospect in the aspect of in vivo delivery of protein medicaments.
Dose escalation to determine the maximum tolerated dose (MTD) of HER2- and HER3- primed DC1 study vaccines. Participants will be treated in cohorts of size three to six and the dosage will be escalated if the clinical toxicity is acceptable. A total of 3 dose levels will be used.
The invention provides a chimeric antigen receptor T lymphocyte for targeted therapy of solid tumors, which is prepared by modifying a chimeric antigen with an amino acid sequence of SEQ ID NO. 1. The invention finally obtains a brand-new chimeric antigen receptor sequence of a target solid tumor Claudin18.2 by screening. The chimeric antigen is inserted into a pLVX-IRES-Neo lentivirus expression vector, and 293T cells of P3 generation are used for packaging lentivirus; after the effectively expanded T cells are plated for 48h, lentiviruses are added for infection, and modified T cells are obtained. Detecting the expression efficiency of the chimeric antigen receptor by using flow cytometry; and the successfully constructed modified T cell is co-cultured with the pancreatic cancer tumor cell positively expressed by Claudin18.2, and the modified T cell has a remarkable killing effect on the PANC-1 cell. The results show that: the constructed CAR-T cell targeting the solid tumor can be used for treating malignant tumors such as pancreatic cancer, gastric cancer, esophageal cancer and the like positively expressed by Claudin18.2.
The present invention relates to a compound disclosed in a formula (1), wherein M stands for K<+> and Na<+> or NH4 <+>. The present invention also relates to a method for preparing the compound, a medical composition and an application thereof in the treatment for resisting tumor endothelial cells and resisting blood vessel hyperplasia. The preparation method comprises: (Z)-3'-hydroxy-3, 4', 5-trimethoxy stilbene reacts with a phosphorylation reagent to produce a phosphorylation intermediate compound under the existence of an acid-binding agent, and then, the phosphorylation intermediate compound flows back to obtain a product. The compound in the formula (1) not only has favorable inhibitory activity for the growth of various tumor cell strains, but also can be combined with microtubulin in tumor vessel endothelial cells for inhibiting the polymerization of the tumor vessel endothelial cells and avoiding mitosis to block the blood vessels which supply oxygen gas and nutrition for tumors, and performs a target anti blood vessel resistance function to cause the death of the tumor cells from lack of blood. In addition, the compound with low concentration can drop abnormally proliferous endothelial cells off by morphological change. Thus, the compound in the formula (1) can be used for controlling tumors and resisting blood vessel hyperplasia.
The invention relates to a Tibetan medicine preparation for treating essential hypertension and a preparation method of the Tibetan medicine preparation. The Tibetan medicine preparation is prepared from the following raw materials in parts by weight: 100-200 parts of wood core parts of caragana jubata (pall.) Poir. or caraganachangduensis fiauf, 50-150 parts of dried overground parts of corydalis racemosa (Thunb.) pers, 50-150 parts of dried herbs of Lagotis brevituba Maxim, 50-150 parts of dried herbs of corydalis hendersonii Hemsl.(C.nepaiesis kitamura) and C.mucionifera Maxim., 50-150 parts of paste of dried wood of rhamnus parvifolia Bunge or 500-1,500 parts of dried wood of rhamnus parvifolia Bunge, and 80-180 parts of dried mature fruits of phyllanthus emblica L. The Tibetan medicine preparation provided by the invention has the effects of treating the essential hypertension and reducing blood pressure, and can be used for preparing a medicine for reducing blood pressure.
The invention discloses fructus choerospondiatis soluble granules capable of promoting qi and activating blood, and a preparation method thereof. The fructus choerospondiatis soluble granules are prepared from fructus choerospondiatis, Japanese raspberry herb, honey, mahonia bealei leaf, piperwallichii (miq.)hand.-mazz.varhupehense (DC.) Hand.-mazz., herba portulacae, folium isatidis, Chinese wolfberry, monochoria vaginalis preslvar. pauciflora (Bl.) merr. leaf, herba equiseti hiemalis, Chinese yam, rhizoma gastrodiae, xylooligosaccharide, rock candy, and microcrystalline cellulose. The preparation method comprises following steps: raw material pretreatment; preparation of a mixed extracting solution, condensation, drying, smashing, mixing, pelletizing, drying, granule shaping, and bagging. The fructus choerospondiatis soluble granules are capable of promoting qi and activating blood, and nourishing heart and tranquilizing mind to different degrees for patients with Qi-stagnancy and blood stasis, obstruction of qi in the chest, and pain, possesses health care effect, and are pure natural; effect is achieved quickly; and no toxic or side effect is caused.
PrismaSATE is another replacement solution used in Continuous Renal Replacement Therapy. The one to be used in this study has bicarbonate concentration of 32 mmol/L.
PCT No. PCT/JP97/01329 Sec. 371 Date Dec. 19, 1997 Sec. 102(e) Date Dec. 19, 1997 PCT Filed Apr. 17, 1997 PCT Pub. No. WO97/39769 PCT Pub. Date Oct. 30, 1997The present invention provides a pharmaceutical composition for treatment of corneal and conjunctival lesion, and dry eye comprising albumin as an active ingredient. The pharmaceutical composition is also useful for increase of eye surface epithelium mucin secretion. The present invention further provides a method for treatment of corneal and conjunctival lesion, and dry eye, which comprises administering, to a subject in need of such treatment, albumin in an amount effective. In addition, the present invention provides a use of albumin for manufacture of a pharmaceutical composition of the present invention.
AIM: While postoperative C-reactive protein (CRP) is used routinely as an early indicator of anastomotic leak (AL), preoperative CRP remains to be established as a potential predictor of AL for elective colorectal surgery. The aim of this systematic review and meta-analysis is to examine the association between preoperative CRP and postoperative complications including AL.
METHOD: MEDLINE, EMBASE, Web of Science, PubMed, Cochrane Library and CINAHL databases were searched. Studies with reported preoperative CRP values and short-term surgical outcomes after elective colorectal surgery were included. An inverse variance random effects meta-analysis was performed for all meta-analysed outcomes to determine if patients with or without complications and AL differed in their preoperative CRP levels. Risk of bias was assessed with MINORS and certainty of evidence with GRADE.
RESULTS: From 1945 citations, 23 studies evaluating 7147 patients were included. Patients experiencing postoperative infective complications had significantly greater preoperative CRP values [eight studies, n = 2421 patients, mean difference (MD) 8.0, 95% CI 3.77-12.23, p < 0.01]. A significant interaction was observed with subgroup analysis based on whether patients were undergoing surgery for inflammatory bowel disease (X2 = 8.99, p < 0.01). Preoperative CRP values were not significantly different between patients experiencing and not experiencing AL (seven studies, n = 3317, MD 2.15, 95% CI -2.35 to 6.66, p = 0.35), nor were they different between patients experiencing and not experiencing overall postoperative morbidity (nine studies, n = 2958, MD 4.54, 95% CI -2.55 to 11.62, p = 0.31) after elective colorectal surgery.
CONCLUSION: Higher preoperative CRP levels are associated with increased rates of overall infective complications, but not with AL alone or with overall morbidity in patients undergoing elective colorectal surgery.
Although inpatient treatment provides immediate stabilization and crisis management for suicidal patients, the risk of suicide post-discharge is substantial, with approximately one third of all suicides by individuals with mental disorders occurring in the 90 days following hospitalization. These data highlight the importance of establishing an empirically-supported inpatient treatment for suicide prevention. Cognitive behavioral therapy (CBT) is a strong candidate, given that CBT reduces risk in suicidal outpatients. In addition, an open trial was completed that 1) adapted the strongest outpatient CBT protocol for an inpatient setting, 2) demonstrated high levels of feasibility and acceptability, and 3) obtained preliminary estimates of efficacy. The objective here is to conduct a largescale randomized controlled trial (RCT) comparing brief cognitive-behavioral therapy for suicide prevention (BCBT) (n = 100) to treatment as usual (TAU, n = 100) to firmly establish efficacy and collect pilot data on treatment implementation metrics. This study aims to determine the efficacy of inpatient BCBT on suicidal behavior, suicidal ideation/intent, and readmission post-treatment and over a 6-month follow-up period. The central hypothesis, based on strong outpatient data, is that inpatient BCBT will reduce suicidal behavior, suicidal ideation/intent, and inpatient readmission over 6 months post-discharge, compared to TAU. Participants will be recruited after inpatient admission following a suicide attempt or with suicidal ideation and plan with suicide attempt within the previous two years. Participants assigned to the BCBT condition will receive four BCBT sessions in addition to treatment as usual. Assessments will occur at intake, discharge, and monthly for six months post-discharge. The proposed study will inform best practices treatment for hospitalized suicidal patients by establishing for the first time, and ultimately disseminating, an empirically-validated inpatient treatment for suicide prevention.
This arm of the single system experimental design starts with a baseline phase of 8 weeks where the subjects are introduced into to the interactive web-based self-help program. The baseline-period is followed by the intervention period which consists of a continued use of the interactive web-based self-help program, now with with cognitive behavioral therapy coaching in combination with individually tailored physiotherapy according to the person's needs for 16 weeks.
This study is an investigation of the short-term effects of two different diets on both conventional as well as newer markers of vascular health among subjects over the age of 50 who have a cardiovascular risk factor. The low-carbohydrate diet will be consistent with low-carbohydrate diet maintenance plans, with "net" carbs kept under 50g per day. The whole-food, plant-based diet will exclude animal foods, oils, and solid fats. Meals will be provided, and subjects will consume each diet for 2 weeks, with a 4-6 week washout period between dietary phases. Subjects will be randomized 1:1 to start with either the plant-based diet or the low-carbohydrate diet. Its primary aim is to assess the short-term effect of a whole-food, plant-based diet and a low-carbohydrate diet on levels of endothelial progenitor cells and trimethylamine N-oxide among this population. Secondarily, we will assess more conventional measures of vascular risk, including cholesterol, weight, blood pressure, insulin resistance, and inflammatory marker, as well as fullness and changes in nutritional intake.
Participants will have access to content focused on general knowledge and injunctive and descriptive norms related to alcohol use and sex. Additionally, participants will have access to content focused on sexual violence including basic information and bystander intervention. This content will be available for a period up to 3 weeks.